Archive for the ‘References’ Category

1. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol
   1992; 126 (Suppl. 39): 23–7.
2. Sais G, Jucgla J, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758–61.
3. Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699–703.
4. Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in north eastern Ohio for other conditions. Arch Dermatol 1997; 133: 1172–3.
5. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis and tinea manuum caused by non dermatophyte filamentous fungi. Mycoses 1989; 32: 609–19.
6. Evans EGV, Gentles JC. Essentials of Medical Mycology. Edinburgh: Churchill Livingstone, 1985.
7. Detandt M, Nolard M. Fungal contamination of the floors of swimming pools, particularly subtropical swimming paradises. Mycoses 1995; 38: 509–13.
8. Drake LA, Sher RK, Smith EB et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998; 38: 702–4.
9. English MP, Atkinson E. Nail mycology in chiropody patients. Br J Dermatol 1974; 91: 67–72.
10. Zaug M, Bergstraesser M. Amorolfine in onychomycosis and dermatomycosis. Clin Exp Dermatol 1992; 17 (Suppl. 1): 61–70.
11. Hay RJ, MacKie RM, Clayton YM. Tioconazole nail solution – an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111–15.
12. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost effective treatment for onychomycosis. Br J Dermatol 2001; 145 (Suppl. 60): 15–19.
13. Roobol A, Gull K, Pogson CI. Griseofulvin-induced aggregation of microtubule protein. Biochem J 1977; 167: 39–43.
14. Wehland DJ, Herzoy W, Weber K. Interaction of griseofulvin with microtubules, microtubular proteins and tubulin. J Mol Biol 1977; 111: 329–42.
15. Roobol A, Gull K, Pogson CI. Evidence that griseofulvin binds to a microtubular protein. FEBS Lett 1977; 29: 149–53.
16. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. Br Med J 1967; iii: 464–8.
17. Faergemann J, Andreson C, Hersle K et al. Double-blind, parallel group comparison of terbinafine and griseofulvin in treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32: 750–3.
18. Haneke E, Tausch I, Brautigam M et al. Short duration treatment of fingernail dermatophytosis: a randomised double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72–7.
19. Hofmann H, Brautigam M, Weidinger G et al. Treatment of toenail onychomycosis. A randomised, double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919–22.
20. Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis. Open and double-blind studies. Acta Derm Venereol (Stockh) 1990; 70: 137–40.
21. Korting HC, Schafer-Korting M, Zienicke H et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother 1993; 37: 2064–8.
22. Cribier BJ, Paul C. Long-term efficacy of antifungals in toenail onychomycosis: a critical review. Br J Dermatol 2001; 145: 446–52.
23. Ryder NS, Favre B. Antifungal activity and mechanism of action of terbinafine. Rev Contemp Pharmcother 1997; 8: 275–88.
24. Ryder NS, Leitner I. In vitro activity of terbinafine; an update. J Dermatol Treat 1998; 9 (Suppl. 1): S23–8.
25. Clayton YM. Relevance of broad spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 (Suppl. 43): 7–8.
26. Faergemann J. Pharmacokinetics of terbinafine. Rev Contemp Pharmacother 1997; 8: 289–97.
27. Brautigam M, Nolting S, Schopf RE et al. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. Br Med J 1995; 311: 919–22.
28. de Backer M, de Keyser P, de Vroey C et al. 12 week treatment for dermatophyte toenail onychomycosis: terbinafine 250 mg vs itraconazole 200 mg per day: a double-blind comparative trial. Br J Dermatol 1996; 134 (Suppl. 46): 16–17.
29. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomised comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34: 138–43.
30. Tosti A, Piraccini BM, Stinchi C et al. Treatment of dermatophyte nail infections: an open randomised study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent intraconazole therapy. J Am Acad Dermatol 1996; 34: 595–600.
31. Evans EGV, Sigurgeirsson B, Billstein S. European multicentre study of continous terbinafine vs intermittent itraconazole in the treatment of toenail onychomycosis. Br Med J 1999; 318: 1031–5.
32. Sigurgeirsson B, Olaffson JH, Steinssen JB et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353–7.
33. Crawford F, Young P, Godfrey C et al. Oral treatments for toenail onychomycosis. A systematic review. Arch Dermatol 2002; 138: 811–16.
34. Gupta AK, Shear NJ. The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Dermatol Venereol 1999; 13: 1–3.
35. Gupta AK, Gregurek-Novak T. Efficacy of itraconzole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001; 202: 235–8.
36. Gupta AK, Daniel CR. Factors that may affect the response of onychomycosis to oral antifungal therapy. Australas J Dermatol 1998; 39: 222–4.
37. Roberts DT, Evans EGV. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998; 138: 189–90.
38. Griffiths CEM. The British Association of Dermatologists guidelines for the management of skin disease. Br J Dermatol 1999; 141: 396–7.
39. Cox NH, Williams HC. The British Association of Dermatologists therapeutic guidelines: can we AGREE? Br J Dermatol, in press.